"If you can diagnose a medical disorder more efficiently, you can treat it more efficiently, and you eliminate a lot of unnecessary tests in between," he says.
NuView plans to reopen a shuttered Texas manufacturing facility to produce both rubidium-82 and technetium-99, Crowe says, and the company aims to have both radioisotopes on the market in 16 to 18 months.
NuView is also working on new radioisotopes, in conjunction with Peter Conti, MD, PhD, professor of radiology and director of the at Keck School of Medicine Molecular Imaging Center at the University of Southern California, utilizing adenosine.
The new products will be available in the next 34 [or] 36 months, providing clinicians with alternatives to technetium-99 or rubidium-82, Crowe says.
Scott Mace is the former senior technology editor for HealthLeaders Media. He is now the senior editor, custom content at H3.Group.